Board Meeting Details

The Board of Directors meeting was held on 12th November, 2026, commencing at 12:19 Hrs. and concluding at 13:35 Hrs. The board approved the Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2026.

Financial Results Overview (₹ in Lakhs)

Quarter Ended 30.09.2026:

  • Revenue from operations: ₹7,845.87
  • Total income: ₹7,845.87
  • Total expenses: ₹7,184.72
  • Profit before tax: ₹661.15
  • Tax expense: ₹172.47 (Current tax: ₹81.78, Deferred tax: ₹90.69)
  • Profit for the period: ₹488.68
  • Earnings per share (Basic & Diluted): ₹2.19

Quarter Ended 30.06.2026:

  • Revenue from operations: ₹9,039.42
  • Profit for the period: ₹465.96
  • EPS: ₹2.09

Quarter Ended 30.09.2025:

  • Revenue from operations: ₹5,414.14
  • Loss for the period: ₹(128.19)
  • EPS: ₹(0.57)

Half Year Ended 30.09.2026:

  • Revenue from operations: ₹16,885.29
  • Profit before tax: ₹1,285.54
  • Tax expense: ₹330.90 (Current tax: ₹162.49, Deferred tax: ₹168.41)
  • Profit for the period: ₹954.64
  • EPS: ₹4.27

Half Year Ended 30.09.2025:

  • Revenue from operations: ₹11,277.62
  • Loss for the period: ₹(174.28)
  • EPS: ₹(0.78)

Key Financial Metrics

  • EBIDTA (Q2 FY27): ₹1,033.73
  • Employee benefits expense (Q2 FY27): ₹746.18
  • Depreciation and amortization (Q2 FY27): ₹370.08
  • Finance costs (Q2 FY27): ₹2.50
  • Paid-up equity share capital: ₹1,117.11 (Face value ₹5 each)

Cash Flow Statement (H1 FY27, ₹ in Lakhs)

  • Net cash from operating activities: ₹1,254.50
  • Net cash used in investing activities: ₹(415.16)
  • Net cash used in financing activities: ₹(831.83)
  • Net increase in cash: ₹7.51
  • Closing cash balance: ₹31.81

Balance Sheet Position (₹ in Lakhs)

  • Total assets (30.09.2026): ₹70,507.44
  • Property, plant and equipment: ₹53,678.56
  • Inventories: ₹6,742.55
  • Trade receivables: ₹5,005.25
  • Total equity: ₹53,238.00
  • Current liabilities: ₹10,535.83

Demerger Accounting

The financial results reflect the demerger of the biopharma undertaking from India Glycols Limited effective April 1, 2026, approved by NCLT on July 17, 2026, and filed with ROC on September 1, 2026. Comparative figures have been restated for comparability using the pooling of interest method under Ind AS 103.

Auditor Review

The financial results were reviewed by the statutory auditors, K N Gutgutia & Co., who issued an unmodified review report noting that the figures for comparative periods have been extracted from India Glycols Limited's financial information and were not separately audited or reviewed by them.